Laboratory and clinical signs of progression monoclonal gammapathy of undetermined significance and multiple myeloma in patients
Abstract
Multiple myeloma (MM) is one of the dyscrasia of lymphoid origin, the terminal differentiation of B-lymphocytes - plasma cells. In its development, MM undergoes a stage of monoclonal gammopathy of undetermined significance (MGUS) and smoldering or asymptomatic myeloma. One of the important aims of the diagnosis of multiple myeloma (MM) is its diagnosis in the early stages, with the possible determination of prognostic factors of progression. Determination of prognostic factors based on a study of immunophenotypic markers of progression, the microenvironment of bone marrow cells, may help to initially identify patients of risk groups for progression, which is important in terms of time of starting specific therapy. In this article, we have analyzed clinical and laboratory data, data on immunophenotypic, cytogenetic, molecular genetic and histological methods for examining patients in the early stages of development - MGUS and at newly diagnosed MM.
About the Authors
Zh. . Kozich
ГУ «РНПЦ радиационной медицины и экологии человека»
Russian Federation
Russian Federation
V. . Martinkov
ГУ «РНПЦ радиационной медицины и экологии человека»
Russian Federation
Russian Federation
D. . Zinovkin
УО «Гомельский государственный медицинский университет»
Russian Federation
Russian Federation
A. . Silin
ГУ «РНПЦ радиационной медицины и экологии человека»
Russian Federation
Russian Federation
M. . Zhandarov
ГУ «РНПЦ радиационной медицины и экологии человека»
Russian Federation
Russian Federation
Zh. . Pugacheva
ГУ «РНПЦ радиационной медицины и экологии человека»
Russian Federation
Russian Federation
L. . Korotaeva
ГУ «РНПЦ радиационной медицины и экологии человека»
Russian Federation
Russian Federation
L. . Smirnova
УО «Белорусская медицинская академия последипломного образования»
Russian Federation
Russian Federation
References
1. Agarwal, A. Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple Myeloma: A Review of the Current Understanding of Epidemiology, Biology, Risk Stratification, and Management of Myeloma Precursor Disease / A. Agarwal, I.M. Ghobrial // Clin. Cancer Res. - 2013. - Vol. 19, № 5. - P. 985-994.
2. Prevalence of monoclonal gammopathy of undetermined significance / R.A. Kyle [et al.] // N. Engl. J. Med. - 2006. - Vol. 354, № 13. - P. 1362-1369.
3. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management / R.A. Kyle [et al.] // Leukemia. - 2010. - Vol. 24, № 6. - P. 1121-1127.
4. Zingone, A. Pathogenesis of Monoclonal Gammopathy of Undetermined Significance and Progression to Multiple Myeloma / A. Zingone, W.M. Kuehl // Semin. Hematol. - 2011. - Vol. 48, № 1. - P. 4-12.
5. Rajkumar, S.V. Multiple Myeloma: Diagnosis and Treatment / S.V. Rajkumar, S. Kumar // Mayo Clin. Proc. - 2016. - Vol. 91, № 1. - P. 101-119.
6. Utility of flow cytometry immunophenotyping in multiple myeloma and other clonal plasma cell-related disorders / B. Paiva [et al.] // Cytometry B. Clin. Cytom. - 2010. - Vol. 78, № 4. - P. 239-252.
7. The Assessment of CD56 and CD117 Expressions at the Time of the Diagnosis in Multiple Myeloma Patientsple Myeloma Patients / F. Ceran [et al.] // Turkish J. Hematol. - 2017. - Vol. 34, № 3. - P. 226.
8. Prevalence of myeloma precursor state monoclonal gammopathy of undetermined significance in 12372 individuals 10-49 years old: a population-based study from the National Health and Nutrition Examination Survey / O. Landgren [et al.] // Blood Cancer J. - 2017. - Vol. 7, № 10. - P. e618-e618.
9. New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells / E. Pérez-Persona [et al.] // Blood. - 2007. - Vol. 110, № 7. - P. 2586-2592.
10. Widespread Genetic Heterogeneity in Multiple Myeloma: Implications for Targeted Therapy /j.G. Lohr [et al.] // Cancer Cell. - 2014. - Vol. 25, № 1. - P. 91-101.
11. High incidence of N and K-Ras activating mutations in multiple myeloma and primary plasma cell leukemia at diagnosis / S. Bezieau [et al.] // Hum. Mutat. - 2001. - Vol. 18, № 3. - P. 212-224.
12. Conventional diagnostics in multiple myeloma /j.F. San Miguel [et al.] // Eur. J. Cancer. - 2006. - Vol. 42, № 11. - P. 1510- 1519.
Review
For citations:
Kozich Zh., Martinkov V., Zinovkin D., Silin A., Zhandarov M., Pugacheva Zh., Korotaeva L., Smirnova L. Laboratory and clinical signs of progression monoclonal gammapathy of undetermined significance and multiple myeloma in patients. Medical and Biological Problems of Life Activity. 2019;(2):90-98. (In Russ.)
Views: 145
Email this article 